[
  {
    "ts": "2026-02-08T14:44:00+00:00",
    "headline": "The Dow Surged Past 50,000. How It Got There, and Where It Goes Next.",
    "summary": "The broader market passed a significant milestone thanks to big gains for stocks outside of tech. Goldman Sachs and Caterpillar are examples.",
    "url": "https://www.barrons.com/articles/dow-jones-industrial-average-50000-first-time-caterpillar-stock-ff67c63d?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d4d07bd1-e873-3a77-8c7a-e7616a7fd512",
      "content": {
        "id": "d4d07bd1-e873-3a77-8c7a-e7616a7fd512",
        "contentType": "STORY",
        "title": "The Dow Surged Past 50,000. How It Got There, and Where It Goes Next.",
        "description": "",
        "summary": "The broader market passed a significant milestone thanks to big gains for stocks outside of tech. Goldman Sachs and Caterpillar are examples.",
        "pubDate": "2026-02-08T14:44:00Z",
        "displayTime": "2026-02-08T14:44:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d4d07bd1-e873-3a77-8c7a-e7616a7fd512/the-dow-surged-past-50-000-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/f35a04652cba629655d0d9b2e83acf62",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E0RaBu1wy9XDOEmeKdl9HQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/f35a04652cba629655d0d9b2e83acf62.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iUnZIcwdMa1si8LhMd4FbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/f35a04652cba629655d0d9b2e83acf62.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/dow-jones-industrial-average-50000-first-time-caterpillar-stock-ff67c63d?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "GS"
            },
            {
              "symbol": "CAT"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "SHW"
            },
            {
              "symbol": "BA"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-08T18:05:29+00:00",
    "headline": "Amgen Reshapes Inflammation Portfolio As Investors Weigh Cash And Pipeline Shifts",
    "summary": "Amgen ended its collaboration with Kyowa Kirin on the experimental eczema drug rocatinlimab. The company received an FDA request to withdraw Tavneos, a treatment for rare blood vessel disease, due to clinical trial data concerns. These moves point to a refocus of Amgen's therapeutic portfolio in inflammation and rare diseases. For investors tracking NasdaqGS:AMGN, these decisions come with the stock at $384.32 and strong recent share performance, including a 12.4% return over the past week...",
    "url": "https://finance.yahoo.com/news/amgen-reshapes-inflammation-portfolio-investors-180529132.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "cb36d850-adc1-3277-93dc-8f58d13324a7",
      "content": {
        "id": "cb36d850-adc1-3277-93dc-8f58d13324a7",
        "contentType": "STORY",
        "title": "Amgen Reshapes Inflammation Portfolio As Investors Weigh Cash And Pipeline Shifts",
        "description": "",
        "summary": "Amgen ended its collaboration with Kyowa Kirin on the experimental eczema drug rocatinlimab. The company received an FDA request to withdraw Tavneos, a treatment for rare blood vessel disease, due to clinical trial data concerns. These moves point to a refocus of Amgen's therapeutic portfolio in inflammation and rare diseases. For investors tracking NasdaqGS:AMGN, these decisions come with the stock at $384.32 and strong recent share performance, including a 12.4% return over the past week...",
        "pubDate": "2026-02-08T18:05:29Z",
        "displayTime": "2026-02-08T18:05:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-reshapes-inflammation-portfolio-investors-180529132.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-reshapes-inflammation-portfolio-investors-180529132.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "KYKOF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]